Lilly's daily weight-loss pill orforglipron wins approval in China, the country's first oral GLP-1 for weight loss

Chinese tech outlet TMTPost reported on Nov. 12 that China's National Medical Products Administration has approved Eli Lilly's orforglipron, a new drug sold in China under the brand name 穆优达 (Muyouda). According to the report, it's the first oral GLP-1 weight-loss drug approved in China.

First, what GLP-1 means. GLP-1 is a hormone your gut releases after you eat. It helps you feel full sooner, slows how fast your stomach empties and helps control blood sugar. The weight-loss drugs that took off worldwide in the last few years, such as Novo Nordisk's semaglutide and Lilly's tirzepatide, mimic or boost this hormone. But they're mostly weekly injections, and the needles and refrigerated pens put a lot of people off.

Orforglipron is different because it's a "small molecule" drug that can be made into an ordinary tablet taken once a day. According to Lilly's US labeling, it can be taken at any time of day without restrictions on food or water. That sets it apart from the oral version of semaglutide that already exists, which has to be taken on an empty stomach with only a little water.

The approved use in China is specific. It's meant to be used alongside diet and exercise, for two groups of adults: people with obesity, defined as a body mass index (BMI, weight in kilograms divided by height in meters squared) of 30 or more, and people with a BMI between 27 and 30 who also have at least one weight-related condition, such as high blood pressure, abnormal cholesterol, high blood sugar, obstructive sleep apnea or heart disease. For a sense of scale, a BMI of 30 for someone who's 5 feet 7 inches tall works out to roughly 191 pounds.

The drug isn't new to the world. The US Food and Drug Administration approved it on April 1 under the brand name Foundayo. Reuters reported at the time that people taking it in clinical trials lost about 12% to 15% of their body weight. In the US, it opened a new front in the weight-loss pill race between Lilly and Novo Nordisk. China has one of the world's largest populations of people with obesity or overweight, so the approval adds a new option in a very large market.

Some important details aren't clear yet. The TMTPost report didn't mention the price in China, when the drug will actually reach hospitals and pharmacies, or whether it'll be covered by China's national health insurance. Those factors will decide how many people can actually use it.

What it means for you: weight-loss medication now comes as a daily pill as well as a weekly shot, which could be easier for people who hate needles or travel and can't keep injection pens cold. But it's a prescription drug, not a diet supplement. GLP-1 drugs commonly cause stomach side effects like nausea, diarrhea and constipation, and weight can come back after stopping. People who don't meet the approved criteria shouldn't buy it on their own. Anyone interested should see a doctor first.

Original sources published: TMTPost, Nov 12, 2026, 15:23 Beijing time / 2:23 AM EST; Reuters, Apr 1, 2026, 23:41 Beijing time / 11:41 AM EDT